摘要
In this study,we designed and engineered a two-component recombinant fusionprotein antigen as a vaccine candidate against the possible biological threat of Yersinia pestis.Therecombinant F1-V protein was formulated with Alhydrogel.A four-time injection with a dosage of10,20 and 50 ug/mouse in about two months was adopted for vaccination.Serum antibodies and subclassof T helper cells were measured and analyzed.After the final vaccination,the mice were challenged by141 strain with 25- 600 LD50.In conclusion,the recombinant vaccine was capable of inducingprotective immunity against subcutaneous challenge.The level of serum IgG was supposed to be a mainfactor that affected the final protection of challenge.20 ug recombinant protein could induce anendpoint titre of serum IgG as high as 51200,which was enough to afford 100% protection against 400LD50 virulent 141 challenge.The antibody isotype analysis showed that the vaccine inducedpredominantly an lgG1 rather than lgG2a response.Flow cytometric analysis revealed that Alhydrogelsignificantly helped induce a stronger humoral immunity instead of CTL cellular response.Thesefindings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine.
In this study, we designed and engineered a two-component recombinant fusion protein antigen as a vaccine candidate against the possible biological threat of Yersinia pestis. The recombinant F1-V pro-tein was formulated with Alhydrogel. A four-time injection with a dosage of 10, 20 and 50 μg/mouse in about two months was adopted for vaccination. Serum antibodies and subclass of T helper cells were measured and analyzed. After the final vaccination, the mice were challenged by 141 strain with 25― 600 LD50. In conclusion, the recombinant vaccine was capable of inducing protective immunity against subcutaneous challenge. The level of serum IgG was supposed to be a main factor that affected the final protection of challenge. 20 μg recombinant protein could induce an endpoint titre of serum IgG as high as 51200, which was enough to afford 100% protection against 400 LD50 virulent 141 challenge. The antibody isotype analysis showed that the vaccine induced predominantly an IgG1 rather than IgG2a response. Flow cytometric analysis revealed that Alhydrogel significantly helped induce a stronger humoral immunity instead of CTL cellular response. These findings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine.
